Reappraising the Use of Systemic Immunomodulators for Psoriasis and Eczema in the Military

CONCLUSIONS: Systemic treatments have evolved to become highly specific for both eczema and psoriasis. These newer biologics and immunomodulators may be compatible with use in the deployed setting, especially those that have long dosing intervals and proven efficacy and safety. Of the biologics, dupilumab and risankizumab offer the best efficacy, safety, and dosing intervals for atopic dermatitis and psoriasis, respectively. Deucravcitinib is a recently FDA-approved oral immunomodulator for psoriasis that has an excellent safety profile and efficacy. Allowing the use of these medications on deployments will enable more people with moderate to severe psoriasis and eczema to join and remain in the military while receiving effective treatment.PMID:38607726 | DOI:10.1093/milmed/usae139
Source: Military Medicine - Category: International Medicine & Public Health Authors: Source Type: research